Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Stock indices move on earnings, policy changes, and macro data. This intro covers the core catalysts that drive daily swings.
23,761 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
MakeMyTrip faces a pivotal year as makemytrip (mmyt) 2026 earnings reveal growth amid rising costs. This analysis bre...
Eli Lilly’s GLP-1 drugs are redefining growth in obesity and diabetes treatment. This article lays out why the stock ...
OpenAI's ongoing losses highlight the high-cost path of AI leadership. This article explains why two blue-chip AI sto...
The first half of 2026 delivered a sharp downturn for Salesforce as AI-driven disruption and market rotation shook th...
Home Depot’s stock surge followed a better-than-expected quarterly showing, with comps rising and margins improving. ...
Investors often react to headlines about Coinbase and Circle with a knee-jerk fear or optimism. This piece explains w...
Lucid represents a high-risk, high-reward bet in the EV space. Before you consider investing, these three practical f...
Brookfield Corporation just bought back a substantial amount of its own stock. The move raises questions about whethe...
Investing in a high-flying name like SpaceX can spark excitement. This article breaks down two strong reasons to wait...
Aehr Test Systems faces a pivotal Q4 print after the market closes, with AI burn-in demand and bookings in focus as t...
NVIDIA is set to report fiscal Q4 results after the close, with traders betting on a top-line beat and a read on AI d...